SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer Kanda Sangthongpitag, Chang Yong Hu, et al. Mol Cancer Ther 2010;9:642-652
http://www.cancer.gov/drugdictionary/?CdrID=559644 http://www.cancer.gov/drugdictionary/?CdrID=559644 ;
New patented histone deacetylase inhibitors. Novotny-Diermayr V et al. Mol Cancer Ther. 2010 Mar;9(3):642-52.
A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors Andrew Protheroe, Gerhardt Attard, et al. Clin Cancer Res 2009;15:4978-4985
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.